Fliz1 inhibitors are a class of chemical compounds that selectively target the FLIZ1 protein, a zinc finger transcription factor involved in regulating gene expression. These inhibitors work by interfering with the protein's ability to bind DNA, altering transcriptional activity. FLIZ1 contains zinc finger domains, which are motifs commonly found in transcription factors and responsible for specific interactions with DNA sequences. The inhibitors often disrupt these interactions by either directly competing for the DNA-binding domain or altering the structural conformation of FLIZ1, thereby preventing it from binding to its target sequences. Inhibiting FLIZ1 can lead to changes in the expression of a broad array of genes under its regulatory control, affecting cellular processes like differentiation, proliferation, and responses to external stimuli.
Chemically, Fliz1 inhibitors tend to be small molecules designed to fit into the DNA-binding pockets of FLIZ1 or its allosteric sites. Some compounds may also target co-factors required for FLIZ1's activity, thereby preventing the transcription factor from recruiting other proteins essential for forming active transcriptional complexes. Inhibition mechanisms vary, from reversible binding at active sites to covalent modification of crucial residues within the FLIZ1 protein. Many Fliz1 inhibitors are designed with high specificity for this transcription factor to minimize off-target effects and unintended interactions with other proteins. Structural biology techniques like X-ray crystallography and NMR are often employed to optimize the interactions between Fliz1 inhibitors and their target, enabling fine-tuning of their chemical properties for maximum efficacy in biological research applications.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a wide range of kinases potentially involved in Fliz1 activation or stabilization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphatidylinositol 3-kinase (PI3K) inhibitor, can disrupt PI3K-dependent signaling pathways that might regulate Fliz1 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-β type I receptor ALK5, which can modulate the TGF-β signaling pathway that might intersect with Fliz1 regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, can affect Fliz1 by altering the protein synthesis pathways that Fliz1 relies on for its expression. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor that can disrupt cell cycle progression, potentially affecting Fliz1 levels or activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump inhibitor, can lead to increased cytosolic calcium levels which may impact Fliz1 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor, can prevent the degradation of proteins that regulate Fliz1 or its pathways. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
A selective FGFR inhibitor which can disrupt the fibroblast growth factor signaling that may interact with Fliz1 regulatory mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), can alter signaling pathways that potentially control Fliz1 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor known to target BCR-ABL, c-KIT, and PDGFR, can affect signaling pathways regulating Fliz1. | ||||||